The nurse is caring for a client experiencing acute alcohol withdrawal. The nurse understands that safe withdrawal is usually accomplished by administering which class of medication to the client?

Choice A reason: Benzodiazepines are the pharmacological standard of care for the management of acute alcohol withdrawal syndrome (AWS). Alcohol exerts its central nervous system depressant effects primarily through potentiation of gamma-aminobutyric acid (GABA) at the GABA-A receptor and inhibition of N-methyl-D-aspartate (NMDA) glutamate receptors. Chronic alcohol exposure leads to compensatory downregulation of GABA-A receptors and upregulation of NMDA receptors. Upon abrupt cessation of alcohol, this imbalance results in central nervous system hyperexcitability, manifesting as tremor, diaphoresis, tachycardia, hypertension, anxiety, seizures, and potentially life-threatening delirium tremens. Benzodiazepines, such as diazepam, lorazepam, and chlordiazepoxide, restore GABAergic inhibitory tone, suppress excitatory hyperactivity, prevent seizures, and reduce mortality from alcohol withdrawal. Choice B reason: Mood stabilizers such as lithium carbonate, valproate, and carbamazepine are not the primary class of medications used for the management of acute alcohol withdrawal. While valproate and carbamazepine have some evidence as adjunctive agents in alcohol detoxification, they do not address the acute GABAergic deficiency and glutamatergic hyperactivity that underlie the pathophysiology of AWS as effectively or as rapidly as benzodiazepines. Lithium has no established role in alcohol withdrawal management. Mood stabilizers are used in the treatment of bipolar disorder and do not constitute the standard of safe withdrawal management for alcohol use disorder. Choice C reason: Antidepressants, including selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tricyclic antidepressants (TCAs), address dysregulation of monoamine neurotransmitter systems and are indicated for the treatment of major depressive disorder and related conditions. They do not act on GABA-A receptors or NMDA glutamate receptors, which are the primary pharmacological targets in alcohol withdrawal management. Antidepressants have no established efficacy in preventing alcohol withdrawal seizures or delirium tremens and are not part of standard detoxification protocols for acute alcohol withdrawal syndrome. Choice D reason: Antipsychotic medications, such as haloperidol, chlorpromazine, and atypical agents including quetiapine and olanzapine, primarily exert their effects through blockade of dopamine D2 receptors and, in the case of atypicals, serotonin 5-HT2A receptors. They do not address the GABAergic and glutamatergic imbalance central to alcohol withdrawal pathophysiology and have not been shown to reliably prevent alcohol withdrawal seizures. Furthermore, typical antipsychotics lower the seizure threshold, which is particularly dangerous in the context of alcohol withdrawal, where seizure risk is already elevated. Antipsychotics are therefore not the first-line or standard medication class for safe alcohol withdrawal management.